San Francisco startup Framework Therapeutics can be focusing on an oral, once-day-to-day GLP-one drug known as GSBR-1290—the drug surpassed Wall Road’s expectations in June whenever a mid-phase analyze confirmed typical weight loss of all over 6% and it strategies to get started on A